PAI-1 Polymorphisms Have Significant Associations With Cancer Risk, Especially Feminine Cancer

被引:3
|
作者
Wang, Jiaxi [1 ,2 ,3 ,4 ]
Peng, Yuanyuan [1 ]
Guo, Hejia [5 ]
Li, Cuiping [2 ,3 ,4 ,6 ]
机构
[1] Guangxi Med Univ, Coll & Hosp Stomatol, Dept Periodontal & Oral Med, Nanning, Peoples R China
[2] Guangxi Key Lab Oral & Maxillofacial Rehabil & Re, Nanning, Peoples R China
[3] Guangxi Key Lab Oral & Maxillofacial Surg Dis Tre, Nanning, Peoples R China
[4] Guangxi Med Univ, Coll Stomatol, Guangxi Hlth Commiss Key Lab Prevent & Treatment, Guangxi Clin Res Ctr Craniofacial Deform, Nanning, Peoples R China
[5] Guangxi Med Univ, Coll & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Nanning, Peoples R China
[6] Guangxi Med Univ, Coll Stomatol, Med Sci Res Ctr, Nanning, Peoples R China
关键词
cancer; polymorphism; PAI-1; meta-analysis; PLASMINOGEN-ACTIVATOR INHIBITOR-1; 4G/5G POLYMORPHISM; GENE POLYMORPHISMS; SUSCEPTIBILITY; EXPRESSION; SYSTEM; PROBABILITY; ANTIGEN; FALSE; UPA;
D O I
10.1177/15330338211037813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The plasminogen activator inhibitor-1 (PAI-1) was found in many types of tumor cells, which involved in tumorigenesis. Some studies investigated the associations between PAI-1 polymorphisms and various cancers, but the results were inconsistent. So this study did a meta-analysis to assess the strength of relationship between PAI-1 and cancer. Methods: Articles that meet the requirements were searched from PubMed, EMBASE, MEDLINE, Scopus, CNKI, Wanfang and SinoMed electronic databases before June 17th 2021. Stata version 11.2 was performed to merge the odds ratios (ORs) values and calculate 95% confidence intervals (CIs). Stratified analyses were assessed on the basis of types of cancer, ethnicity and source of the control group. Heterogeneity and sensitivity analysis were tested, and publication bias was also estimated. A meta-regression analysis was applied to explore sources of heterogeneity. The false-positive report probabilities (FPRP) and the Bayesian False Discovery Probability (BFDP) test were used to assess the credibility of statistically significant associations. Results: Ultimately, in this study, 33 eligible reports were included with 9550 cases and 10431 controls for the rs1799889 polymorphism, 5 reports with 2705 cases and 3168 controls for the rs2227631 polymorphism, and 4 reports with 2799 cases and 4011 controls for the rs2227667 polymorphism. The ORs and 95% CIs showed a statistically significant relationship between rs1799889 4G>5G polymorphism and cancer risk, especially in feminine cancer. The term refers to cancers that occur in the female reproductive system, such as ovarian, breast, endometrial and cervical cancer. Moreover, there was no association observed for the PAI-1 promoter A>G polymorphism (rs2227631 and rs2227667). In further subgroup analyses of 4G>5G polymorphism (rs1799889), an increased susceptibility to cancer was observed in Caucasians group and some types of cancer groups. Conclusions: This article comes to a conclusion that the rs1799889 polymorphism might help to increase the risk of cancer; moreover, the susceptibility to feminine cancer is more evident.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Significant associations of PAI-1 genetic polymorphisms with osteonecrosis of the femoral head
    Hye- Ok Kim
    Chang- Hoon Cho
    Yoon- Je Cho
    Seong- Ho Cho
    Kyung- Sik Yoon
    Kang- Il Kim
    BMC Musculoskeletal Disorders, 12
  • [2] Significant associations of PAI-1 genetic polymorphisms with osteonecrosis of the femoral head
    Kim, Hye-Ok
    Cho, Chang-Hoon
    Cho, Yoon-Je
    Cho, Seong-Ho
    Yoon, Kyung-Sik
    Kim, Kang-Il
    BMC MUSCULOSKELETAL DISORDERS, 2011, 12
  • [3] PAI-1 - A potential therapeutic target in cancer
    Andreasen, Peter A.
    CURRENT DRUG TARGETS, 2007, 8 (09) : 1030 - 1041
  • [4] Significant associations between GSTM1/GSTT1 polymorphisms and nasopharyngeal cancer risk
    Wei, Yumei
    Zhou, Tao
    Lin, Haiqun
    Sun, Mingping
    Wang, Dongqing
    Li, Hongsheng
    Li, Baosheng
    TUMOR BIOLOGY, 2013, 34 (02) : 887 - 894
  • [5] PAI-1 and PAI-2 as predictive factors in breast cancer
    Matos, E.
    Borstnar, S.
    Vrhovec, I.
    Svetic, B.
    Cufer, T.
    EJC SUPPLEMENTS, 2004, 2 (03): : 181 - 182
  • [6] Predictive value of PAI-1 and PAI-2 in breast cancer
    Matos, E
    Vrhovec, I
    Borstnar, S
    Jagodic, M
    Cufer, T
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S111 - S111
  • [7] PAI-1 polymorphism and expression of uPA, PAI-1 and COX-2 in breast cancer.
    Minisini, AM
    Di Loreto, C
    Pestrin, M
    Fabbro, D
    Cardellino, GG
    Russo, S
    Andreetta, C
    Damante, G
    Piga, A
    Puglisi, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 879S - 879S
  • [8] Compound interest: ACE and PAI-1 polymorphisms and risk of thrombosis and fibrosis
    Fogo, AB
    Vaughan, DE
    KIDNEY INTERNATIONAL, 1998, 54 (05) : 1765 - 1766
  • [9] Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer
    Smolarz, B
    Blasiak, J
    Kulig, A
    Romanowicz-Makowska, H
    Dziki, A
    Ulanska, J
    Pander, B
    Szewczyk, T
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2001, 20 (02) : 247 - 252
  • [10] PAI-1 REGULATES PROSTATE CANCER BUT NOT LUNG CANCER CELLS INVASIVENESS
    Rozy, Adriana
    Kedzior, Marta
    Chorostowska-Wynimko, Joanna
    Jagus, Paulina
    Skronski, Michal
    Szpechcinski, Adam
    Skrzypczak-Jankun, Ewa
    Jankun, Jerzy
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S717 - S717